# Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

> **NCT03207438** · PHASE4 · COMPLETED · sponsor: **University of Saskatchewan** · enrollment: 1790 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Quetiapine 50 MG Extended Release Oral Tablet
- **DRUG:** Quetiapine Fumarate XR 150-300 mg
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03207438
- **Lead sponsor:** University of Saskatchewan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-07
- **Final completion:** 2019-10
- **Target enrollment:** 1790 (ACTUAL)
- **Last updated:** 2019-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207438, "Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03207438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*